teclistamab,daratumumab,talquetamab
genmab,janssen
['mmsm']
aa4: skin/ nail/oral toxicity mainly g1/2 in (35-53%) and dysgeusia was reported in 47% #mmsm #myeloma #medtiwtter #usmirc #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter